Tonix Pharmaceuticals’ $25 Million Acquisition of FDA-Approved Products from Upsher-Smith Laboratories

Laura Testa
Tagged:

Lowenstein represented Tonix Pharmaceuticals Holding Corp. in the transaction.Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceutical company, announced its $25 million acquisition of two currently-marketed…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Laura Testa

Author: Laura Testa

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here